AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMUGENE LTD

0.035

-0.001-2.78%

Volume:8.47M

Turnover:301.72K

Market Cap:261.01M

PE:-1.92

High:0.037

Open:0.037

Low:0.035

Close:0.036

Loading ...

Overview Company News Filings

BRIEF-Imugene Ltd Appoints Darren Keamy As CFO

Imugene Appoints CFO; Shares Fall 3%

MT Newswires Live

Imugene Ltd - Appoints Darren Keamy as CFO and Company Secretary

THOMSON REUTERS

Imugene Ltd - Mike Tonroe Resigns as CFO

THOMSON REUTERS

BRIEF-Imugene Posts HY Net Loss Attributable A$48.3 Million

Imugene - Hy Net Loss Attributable a$48.3 Mln

THOMSON REUTERS

Imugene Receives Patent for Oncolytic Virotherapy Technology in India; Shares Rise 3%

MT Newswires Live

BRIEF-Imugene Granted India Patent For Oncolytic Virotherapy CF33

Imugene Ltd - Imugene Granted India Patent for Oncolytic Virotherapy CF33

THOMSON REUTERS

Imugene Receives Patent for Oncolytic Virus in China

MT Newswires Live

BRIEF-Imugene Says Oncarlytics Patent Allowance In China

Imugene Ltd - Oncarlytics Patent Allowance in China

THOMSON REUTERS

Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher

Imugene Therapy Achieves Two Complete Responses in Patients with Blood Cancer, Shares Rise Past 8%

MT Newswires Live

BRIEF-Imugene Receives A$20 Mln For Convertible Notes Issue

Imugene Receives AU$20 Million From First Tranche of AU$46 Million Capital Raise; Shares Down 3%

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IMU.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IMU.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.035,"timestamp":1741147826355,"preClose":0.036,"halted":0,"volume":8473945,"delay":0,"changeRate":-0.027778,"change":-0.001,"floatShares":6260580705,"shares":7457433979,"eps":-0.018233,"lyrEps":-0.021115,"pbRate":4.12,"amount":301720,"amplitude":0.055556,"volumeRatio":0.522657,"dividePrice":0,"prevYearClose":0.037,"fiveDayClose":0.036,"twentyDayClose":0.036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":6260580705,"roa":"-42.92%","roe":"-100.19%","lyrEps":-0.021115,"volumeRatio":0.522657,"shares":7457433979,"dividePrice":0,"high":0.037,"amplitude":0.055556,"preClose":0.036,"low":0.035,"week52Low":0.035,"pbRate":"4.12","psRate":"-94.66","week52High":0.12,"institutionHeld":0,"latestPrice":0.035,"committee":0.839796,"eps":-0.018233,"divideRate":0,"volume":8473945,"delay":0,"ttmEps":-0.018233,"open":0.037,"prevYearClose":0.037,"prevWeekClose":0.037,"prevMonthClose":0.037,"prevQuarterClose":0.037,"fiveDayClose":0.036,"twentyDayClose":0.036,"sixtyDayClose":0.039},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:16,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516693550","title":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516693550","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516693550?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:25","pubTimestamp":1741047942,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Ltd Appoints Darren Keamy As CFO March 4 (Reuters) - Imugene Ltd IMU.AX:APPOINTS DARREN KEAMY AS CFO AND COMPANY SECRETARYMIKE TONROE RESIGNS AS CFOFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2516660815","title":"Imugene Appoints CFO; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516660815","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516660815?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:35","pubTimestamp":1741044931,"startTime":"0","endTime":"0","summary":"Imugene  appointed Clinuvel Pharmaceuticals'  former Chief Financial Officer Darren Keamy as CFO, effective immediately, according to a Tuesday filing with the Australian bourse.Keamy will succeed current CFO Mike Tonroe, the filing said.Shares of the pharmaceutical company fell 3% in recent trade,Price : $0.04, Change: $-0.00100, Percent Change: -2.78%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","CUV.AU","BK7067","IMU.AU","XKO.AU","BK7508","XAO.AU"],"gpt_icon":0},{"id":"2516661368","title":"Imugene Ltd - Appoints Darren Keamy as CFO and Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661368?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:01","pubTimestamp":1741039295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2516661359","title":"Imugene Ltd - Mike Tonroe Resigns as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516661359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516661359?lang=en_us&edition=fundamental","pubTime":"2025-03-04 06:01","pubTimestamp":1741039295,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM18W:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2514366878","title":"BRIEF-Imugene Posts HY Net Loss Attributable A$48.3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2514366878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514366878?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:34","pubTimestamp":1740706449,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Posts HY Net Loss Attributable A$48.3 MillionFeb 28 (Reuters) - Imugene Ltd IMU.AX:HY NET LOSS ATTRIBUTABLE A$48.3 MILLIONFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI29N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2514351420","title":"Imugene - Hy Net Loss Attributable a$48.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514351420","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514351420?lang=en_us&edition=fundamental","pubTime":"2025-02-28 07:01","pubTimestamp":1740697312,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI29N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2514814255","title":"Imugene Receives Patent for Oncolytic Virotherapy Technology in India; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514814255","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514814255?lang=en_us&edition=fundamental","pubTime":"2025-02-27 10:41","pubTimestamp":1740624075,"startTime":"0","endTime":"0","summary":"Imugene  obtained a patent in India for its exclusively licensed CF33 oncolytic virotherapy technology, according to a Thursday filing with the Australian bourse.The patent is set to expire in 2037. The technology already has intellectual property protection in the US and Japan, the filing said.The clinical-stage immuno-oncology company's shares rose 3% in recent trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2514815226","title":"BRIEF-Imugene Granted India Patent For Oncolytic Virotherapy CF33","url":"https://stock-news.laohu8.com/highlight/detail?id=2514815226","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514815226?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:35","pubTimestamp":1740620134,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Granted India Patent For Oncolytic Virotherapy CF33Feb 27 (Reuters) - Imugene Ltd IMU.AX:IMUGENE GRANTED INDIA PATENT FOR ONCOLYTIC VIROTHERAPY CF33Further company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2514312895","title":"Imugene Ltd - Imugene Granted India Patent for Oncolytic Virotherapy CF33","url":"https://stock-news.laohu8.com/highlight/detail?id=2514312895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514312895?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:59","pubTimestamp":1740607180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1V4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMU.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2514807835","title":"Imugene Receives Patent for Oncolytic Virus in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514807835","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514807835?lang=en_us&edition=fundamental","pubTime":"2025-02-26 10:15","pubTimestamp":1740536115,"startTime":"0","endTime":"0","summary":"Imugene  received a notice of allowance from the Chinese patent office for City of Hope's patent application for the CD19-expressing oncolytic virus, onCARlytics, according to a Wednesday Australian bourse filing.The patent protects the method of composition and method of use of onCARlytics through to 2038.OnCARlytics is exclusively licensed to Imugene and is a CD19-expressing oncolytic virus that enters solid tumor cells, forcing them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies.Its OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites in the US, with up to around 40 patients proposed to take part.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2514027090","title":"BRIEF-Imugene Says Oncarlytics Patent Allowance In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514027090","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514027090?lang=en_us&edition=fundamental","pubTime":"2025-02-26 09:58","pubTimestamp":1740535109,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Says Oncarlytics Patent Allowance In ChinaFeb 26 (Reuters) - Imugene Ltd IMU.AX:ONCARLYTICS PATENT ALLOWANCE IN CHINASource text: ID:nASX4H7R2BFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PG10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2514042775","title":"Imugene Ltd - Oncarlytics Patent Allowance in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2514042775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514042775?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:59","pubTimestamp":1740520782,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PG10Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2511687824","title":"Why GQG, Imugene, Mirvac, and Temple & Webster shares are pushing higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2511687824","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511687824?lang=en_us&edition=fundamental","pubTime":"2025-02-14 10:02","pubTimestamp":1739498540,"startTime":"0","endTime":"0","summary":"In afternoon trade on Friday, theS&P/ASX 200 Index is on course to record a decent gain. At the time of writing, the benchmark index is up 0.4% to 8,574.7 points.Four ASX shares that are rising more than most today are listed below. Here's why they are charging higher:. The Temple & Webster share price is up a further 8% to $17.45. Investors have been bidding the furniture and homeware retailer's shares higher this week following the release of its half year results. Temple & Webster reported a 23.6% increase in revenue to $313.7 million and a 118% jump in net profit after tax to $9 million. The company's CEO, Mark Coulter, said: \"Temple & Webster has again delivered a record half, with strong performance against all key metrics, against a challenging macro and consumer backdrop.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/14/why-gqg-imugene-mirvac-and-temple-webster-shares-are-pushing-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","GQG.AU","BK7107","BK4211","BK7087","MGR.AU","IMU.AU","BK7049","TPW.AU","WBS","BK7508","BK7067","BK7510","BK7062"],"gpt_icon":0},{"id":"2511981683","title":"Imugene Therapy Achieves Two Complete Responses in Patients with Blood Cancer, Shares Rise Past 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511981683","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511981683?lang=en_us&edition=fundamental","pubTime":"2025-02-14 09:41","pubTimestamp":1739497315,"startTime":"0","endTime":"0","summary":"Imugene (ASX:IMU) reported two more complete responses in its phase 1b trial of azer-cel cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma, according to a Friday Australi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2507764495","title":"BRIEF-Imugene Receives A$20 Mln For Convertible Notes Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2507764495","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507764495?lang=en_us&edition=fundamental","pubTime":"2025-01-29 09:23","pubTimestamp":1738113794,"startTime":"0","endTime":"0","summary":"BRIEF-Imugene Receives A$20 Mln For Convertible Notes IssueJan 29 (Reuters) - Imugene Ltd IMU.AX:IMUGENE RECEIVES A$20 MILLION FOR CONVERTIBLE NOTES ISSUEFurther company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250129:nFWN3OO1S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2507573925","title":"Imugene Receives AU$20 Million From First Tranche of AU$46 Million Capital Raise; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507573925","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507573925?lang=en_us&edition=fundamental","pubTime":"2025-01-29 08:26","pubTimestamp":1738110396,"startTime":"0","endTime":"0","summary":"Imugene  received AU$20 million from the issuance of senior, unsecured, zero-coupon convertible notes to CVI Investments, representing the first tranche of a AU$46 million capital raise, according to a Wednesday filing with the Australian bourse.The convertible notes have a five-year maturity, the filing said.Proceeds will be used to advance the company's immuno-oncology clinical trial pipeline, according to the filing.Imugene's shares fell nearly 3% in morning trade Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMU.AU","BK7508","BK7067"],"gpt_icon":0}],"pageSize":16,"totalPage":3,"pageCount":1,"totalSize":48}]}}